Vinpocetine forte

General characteristics. Structure:

One tablet contains 10 mg of a Vinpocetine as active agent,

excipients: hydrophosphate calcium dihydrate (calcium phosphate disubstituted), lactose (sugar milk), povidone (коллидон 25), кросповидон (коллидон CL), magnesium stearate.

Description: Tablets of color, white or white with a yellowish shade, a ploskotsilindrichesky form with a facet.

Pharmacological properties:

Possesses vasodilating, anti-hypoxemic and anti-aggregation action. Inhibits phosphodiesterase and increases the content of cyclic adenosinemonophosphate in cells that leads to decrease in content of calcium in cytoplasm of smooth muscle cells and to relaxation of myofibrils. Expands brain vessels, strengthens a blood stream, it is preferential in ischemic areas, improves supply of a brain with oxygen. Promotes utilization of glucose and increases the level of catecholamines in the central nervous system, stimulates metabolism of noradrenaline and serotonin in brain tissues. Reduces aggregation of thrombocytes, viscosity of blood, promotes increase in deformability of erythrocytes and normalization of venous outflow against the background of decrease in resistance of brain vessels. System arterial pressure slightly goes down. Sensitivity of brain vessels to the running-down action of a Vinpocetine increases in advanced and senile age that is caused by a sensitization of system of an adenitattsiklaza — cyclic adenosinemonophosphate when aging.

Pharmacokinetics. Quickly, bioavailability about 60% is soaked up from digestive tract. The maximum concentration in a blood plasma is reached in 1 hour. Easily gets through gistogematichesky barriers (including through a blood-brain barrier). Elimination half-life about 5 hours.

Indications to use:

Insufficiency of cerebral circulation (including acute and recovery stages of an ischemic stroke, recovery stage of a hemorrhagic stroke, tranzitorny ischemic attack, encephalopathies, multiinfarctive dementia).
Vascular diseases of a retina and/or choroid of an eye (owing to arteriosclerosis, a vasomotor spasm, thrombosis); the degenerative changes of a macula lutea caused by atherosclerosis or a vasomotor spasm; secondary glaucoma (owing to obturation of vessels).
Age vascular or toxic (medicamentous) hearing disorder, Menyer's disease, dizzinesses of a labyrinth origin.
Vegetative manifestations of a menopausal syndrome.

Route of administration and doses:

Inside to 1 tablet 3 times a day within 2 months. Before drug withdrawal it is necessary to reduce a dosage gradually. Repeated courses 2–3 times a year are possible.

Side effects:

Lowering of arterial pressure, tachycardia, premature ventricular contraction, delay of intra ventricular conductivity.

Interaction with other medicines:

Increases risk of hemorrhagic complications against the background of a geparinoterapiya.

Contraindications:

Hypersensitivity, the expressed disturbances of a heart rhythm, coronary heart disease (heavy current), acute stage of a hemorrhagic stroke, pregnancy, the lactation period.

Overdose:

Symptoms: strengthening of expressiveness of side effects. 

Treatment: gastric lavage, reception of absorbent carbon and symptomatic treatment.

Storage conditions:

List B. In dry, protected from light and the place, unavailable to children, at a temperature not above 25 °C. Period of validity: 2 years. Not to use after the date specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Tablets on 10 mg. 10 or 30 tablets in a blister strip packaging. On 1, 3, 5 blister strip packagings on 10 tablets or on 1 blister strip packaging on 30 tablets with the application instruction in a pack from a cardboard.